HOME >> MEDICINE >> NEWS
Imatinib (Gleevec) has activity in AIDS-related Kaposi's sarcoma

Alexandria, VA--A new clinical study has shown that imatinib mesylate (Gleevec) has activity in AIDS-related Kaposi's sarcoma (KS). Imatinib inhibits important pathways that spur cancer growth, resulting in the regression of KS tumors within 4 weeks in some patients. The study will be published November 30 in the Journal of Clinical Oncology (JCO).

"Imatinib is a targeted therapy originally shown to be effective in treating chronic myelogenous leukemia and gastrointestinal stromal tumors. This study and others are showing that the drug is also active in other cancers that express some of the same proteins," said Henry B. Koon, MD, Instructor of Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, and lead author of the study. "Studies like this one represent an exciting time in oncology, when our understanding of the development of diseases like KS coincide with the availability of effective treatments. Further research on imatinib in KS patients will be needed to determine appropriate dosing schedules."

Kaposi's sarcoma is an AIDS-defining illness characterized by soft purplish lesions on the skin, mucous membranes, and internal organs. Although the incidence of KS has declined dramatically in the developed world since the advent of highly active antiretroviral therapies (HAART), it remains a significant cause of morbidity and mortality for AIDS patients in the United States and a major cause of mortality in the third world, given the limited number of effective treatments for KS.

Researchers examined the response of Kaposi's sarcoma to imatinib, a drug known to inhibit the PDGF-R and/or c-kit pathways that are responsible for the growth of other cancers, such as chronic myelogenous leukemia, gastrointestinal stromal tumors (GIST), and bone sarcomas of the head and neck. Given that PDGF-R and c-kit also play a role in the development of KS, researchers theorized that imatinib may be an effective strategy
'"/>

Contact: Danielle Potuto
potutod@asco.org
703-519-1422
American Society of Clinical Oncology
30-Nov-2004


Page: 1 2

Related medicine news :

1. Imatinib shows early promise against Ewings sarcoma
2. Brain activity prior to treatment flags vulnerability to antidepressant side effects
3. Physical activity linked to protection from Parkinsons disease
4. Brain activity of men and women during hostile or impulsive acts differs less on nicotine
5. Abnormal brain activity during the observation of others actions
6. Increased physical activity not linked to ALS risk
7. Maintaining physical activity linked to less cognitive decline in older men
8. Daily social/physical activity improves sleep and cognition in the elderly
9. Celecoxib shows surprising activity against estrogen receptors
10. Jefferson scientists find way to see breast cancer activity from outside the body
11. Brain activity reflects complexity of responses to other-race faces

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Imatinib Gleevec has activity AIDS related Kaposi sarcoma

(Date:8/27/2014)... Delta, a reliable supplier of high quality ... D7R Dozers to its used bulldozer collection. ... that all these items are offered with deep discounts. ... Delta’s market share in the coming September. , ... offer; he has much confidence in the discounted Used ...
(Date:8/27/2014)... Philadelphia, PA. Inc. magazine ranked Holganix as No. ... exclusive ranking of the nation’s fastest-growing privately held companies. ... most important segment of the economy - America’s independent ... members of the Inc. 500 list include Dell, LinkedIn, ... world’s greatest companies have had their start on the ...
(Date:8/27/2014)... Diego, CA (PRWEB) August 27, 2014 ... insurance policies will now be easier for the public ... insurance prices that are promoted in all 50 states ... . , The different insurers that are generating ... made it possible for adults to use the programmed ...
(Date:8/27/2014)... August 27, 2014 Today, Zane Benefits, ... on compliance tips for administering a premium reimbursement plan. ... in full effect, compliance is top of mind for ... to individual health insurance and premium reimbursement, there are ... In the 35 minute webinar, Zane Benefits President, Rick ...
(Date:8/27/2014)... (PRWEB) August 28, 2014 Top 10 Best ... compared many Linux hosting suppliers and announced iPage, Bluehost and ... USA, UK, Canada, Australia and Europe to buy useful hosting ... the most reliable suppliers, iPage has been serving ... years’ development, it has grown into a leader in the ...
Breaking Medicine News(10 mins):Health News:Reliable Supplier Delta Adds New Items To Its Used Bulldozer Collection 2Health News:Inc Magazine Unveils 33rd Annual List of America's Fastest-Growing Private Companies - the Inc. 500 2Health News:Home Insurance Prices for All 50 States Now Supplied at Consumer Insurance Portal Online 2Health News:Zane Benefits Announces Upcoming Webinar on Compliance 2Health News:Well-known SEO Hosts Review Site Top10BestSEOHosting.com Recommends iPage, Bluehost and GoDaddy To Webmasters 2
(Date:8/27/2014)... 27, 2014 Reportbuyer.com has added ... Co-development Terms & Agreements in Pharma, Biotech ... The Co-development Terms and Agreements ... comprehensive understanding and unprecedented access to the ... the worlds leading life science companies. ...
(Date:8/27/2014)... and MENLO PARK, Calif. , Aug. ... DMPI), developer of advanced cancer therapeutics , will ... Annual Rodman & Renshaw Global Investment Conference, sponsored by ... take place Tuesday, September 9th at 2:55 p.m. EDT ... New York Palace Hotel in New York ...
(Date:8/27/2014)... , Aug. 27, 2014 Research ... "Global Pulse Oximeter Industry Report 2014" report to ... Industry Report 2014 is a professional and in-depth study ... industry. The report provides a basic overview ... chain structure. The pulse oximeter market analysis is provided ...
Breaking Medicine Technology:Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 2Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 3Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 4Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 5Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 6Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 7DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 2DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 3DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 4Global Pulse Oximeter Industry Report 2014 2
Cached News: